These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31188000)

  • 1. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.
    Ferrarini A; Di Poto C; He S; Tu C; Varghese RS; Kara Balla A; Jayatilake M; Li Z; Ghaffari K; Fan Z; Sherif ZA; Kumar D; Kroemer A; Tadesse MG; Ressom HW
    J Proteome Res; 2019 Aug; 18(8):3067-3076. PubMed ID: 31188000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice.
    Fan T; Rong Z; Dong J; Li J; Wang K; Wang X; Li H; Chen J; Wang F; Wang J; Wang A
    Cancer Med; 2017 Oct; 6(10):2370-2384. PubMed ID: 28941178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.
    Beyoğlu D; Imbeaud S; Maurhofer O; Bioulac-Sage P; Zucman-Rossi J; Dufour JF; Idle JR
    Hepatology; 2013 Jul; 58(1):229-38. PubMed ID: 23463346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy.
    Ng SSW; Jang GH; Kurland IJ; Qiu Y; Guha C; Dawson LA
    EBioMedicine; 2020 Sep; 59():102973. PubMed ID: 32891936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes.
    Budhu A; Roessler S; Zhao X; Yu Z; Forgues M; Ji J; Karoly E; Qin LX; Ye QH; Jia HL; Fan J; Sun HC; Tang ZY; Wang XW
    Gastroenterology; 2013 May; 144(5):1066-1075.e1. PubMed ID: 23376425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
    Huang Q; Tan Y; Yin P; Ye G; Gao P; Lu X; Wang H; Xu G
    Cancer Res; 2013 Aug; 73(16):4992-5002. PubMed ID: 23824744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort.
    Nezami Ranjbar MR; Luo Y; Di Poto C; Varghese RS; Ferrarini A; Zhang C; Sarhan NI; Soliman H; Tadesse MG; Ziada DH; Roy R; Ressom HW
    PLoS One; 2015; 10(6):e0127299. PubMed ID: 26030804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel biomarkers of hepatocellular carcinoma by high-definition mass spectrometry: Ultrahigh-performance liquid chromatography quadrupole time-of-flight mass spectrometry and desorption electrospray ionization mass spectrometry imaging.
    Nagai K; Uranbileg B; Chen Z; Fujioka A; Yamazaki T; Matsumoto Y; Tsukamoto H; Ikeda H; Yatomi Y; Chiba H; Hui SP; Nakazawa T; Saito R; Koshiba S; Aoki J; Saigusa D; Tomioka Y
    Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1(Suppl 1):e8551. PubMed ID: 31412144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
    Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
    Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.
    Patterson AD; Maurhofer O; Beyoglu D; Lanz C; Krausz KW; Pabst T; Gonzalez FJ; Dufour JF; Idle JR
    Cancer Res; 2011 Nov; 71(21):6590-600. PubMed ID: 21900402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-targeted metabolomics study for discovery of hepatocellular carcinoma serum diagnostic biomarker.
    Wang S; He T; Wang H
    J Pharm Biomed Anal; 2024 Feb; 239():115869. PubMed ID: 38064771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS.
    Baniasadi H; Gowda GA; Gu H; Zeng A; Zhuang S; Skill N; Maluccio M; Raftery D
    Electrophoresis; 2013 Oct; 34(19):2910-7. PubMed ID: 23856972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 18. Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
    Liu J; Geng W; Sun H; Liu C; Huang F; Cao J; Xia L; Zhao H; Zhai J; Li Q; Zhang X; Kuang M; Shen S; Xia Q; Wong VW; Yu J
    Gut; 2022 Jun; 71(6):1203-1213. PubMed ID: 34344785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
    Darpolor MM; Basu SS; Worth A; Nelson DS; Clarke-Katzenberg RH; Glickson JD; Kaplan DE; Blair IA
    NMR Biomed; 2014 Apr; 27(4):381-9. PubMed ID: 24497316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.